Where does Lyvgen Biopharma Holdings Limited rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Lyvgen Biopharma Holdings Limited ranks #41,524 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Lyvgen Biopharma Holdings Limited hold?

Lyvgen Biopharma Holdings Limited holds 6 US utility patents granted between 2021 and 2024, spanning 4 technology areas.

What is Lyvgen Biopharma Holdings Limited's Innovation Score?

Lyvgen Biopharma Holdings Limited has an Innovation Score of 28.9 out of 100 (29th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Lyvgen Biopharma Holdings Limited's patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for Lyvgen Biopharma Holdings Limited.

What does claim depth mean for Lyvgen Biopharma Holdings Limited's patents?

Lyvgen Biopharma Holdings Limited's patents average 14.0 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Lyvgen Biopharma Holdings Limited patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Lyvgen Biopharma Holdings Limited

Q: What technology areas does Lyvgen Biopharma Holdings Limited focus on?

Lyvgen Biopharma Holdings Limited's top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 6 patents. Grants appear in 4 CPC subclasses total.

USPTO PatentsView assignee record - 6 granted patents across 4 technology areas, recorded in grant years 2021–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Lyvgen ranks #41,524 of 49,997 tracked US assignees by granted-patent volume, with 6 patents across 4 technology areas.

#41,524
of 49,997 US assignees by volume: 29th percentile
by Innovation Score (28.9/100): 14.0
avg claims per patent

USPTO PatentsView assignee plate

Corpus R41524 · Foreign Corporation #41,524 · 6 grants

GRANTS-MICRO · LOWER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · SPAN-YRS · BOOK-RICH

GRANTS-MICRO 6 grants
LOWER-Q #41,524/49,997
PHOTO-FINISH LaaSer Critical…
CPC-NARROW A61P · 4 areas
INNOV-THIN 28.9/100
CLAIMS-RICH 14.0 claims/avg
TYPE-FRNCORP Foreign Corp
SPAN-YRS 2021–2024 · 4y
BOOK-RICH 9/10 fields

Nearest grant-volume peer: LaaSer Critical Communications Corp. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Gems Sensors · near

29
HotStart · near

29
Lyvgen Biopharma… · this assignee

29
RUNNER(XIAMEN) · near

29
Seari Electric… · near

29
3D Lighting… · lowest

7

What this shows Lyvgen's Innovation Score is 28.9/100 (29th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where Lyvgen's grants concentrate

Lyvgen Biopharma Holdings Limited is a focused PatentsView assignee: 4 CPC subclasses with 100% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2021 (3 grants) versus a trough of 1 in 2022. By volume, Lyvgen sits between Lure Enterprises Limited Liability Company and Ladies & Gentlemen Studio, Inc..

Lyvgen's three-year grant acceleration

Lyvgen Biopharma Holdings Limited shows 3 grants in 2022–2024 against only 3 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Lure Enterprises…

6
LUX BIO Group

6
LWE

6
Lynceus SAS

6
Laaser Critical C…

6
Laava ID Pty

6
Labyrinth Research

6
Ladies & Gentleme…

6
Lyvgen Biopharma… ◀

6

What this shows Lyvgen holds 6 patents at rank #41,396, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Lyvgen

By rank, the assignees closest to #41,396 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Lyvgen's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Lyvgen, neither rank-band nor same-CPC leaders (those blocks stay above).

Similar innovation score

Nearest assignees by Innovation Score (29 here).

HotStart, Inc. 29 Gems Sensors Inc. 29 RUNNER(XIAMEN) Corp. 29 Seari Electric Technology Co., Ltd. 29

Lyvgen's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

29 29th percentile higher than 29% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2021–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2021–2019 baseline. Full figures in the table below.

View data table

Lyvgen Biopharma Holdings Limited patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2021	3	50.0%
2022	1	16.7%
2024	2	33.3%

Which technologies does Lyvgen Biopharma Holdings Limited patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 6

C07K - Peptides 6

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 5

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 1

Top 4 of 4 technology areas

Where it ranks

Overall rank by patents

#41,524

of 49,997 tracked assignees

Innovation Score

28.9 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Lyvgen Biopharma Holdings Limited's patent record in context - here's where to go next.

Lyvgen Biopharma Holdings Limited's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 100% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #41,524 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Lyvgen Biopharma Holdings Limited against Lure Enterprises Limited Liability Company, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 28.9/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.